Notre Dame Test Aims to Calm Peanut Panic

Posted: Updated:
While Bilgicer is developing the method for peanuts, he says it could be applicable for any food allergy. While Bilgicer is developing the method for peanuts, he says it could be applicable for any food allergy.

Archaic, dangerous and traumatic is how a University of Notre Dame researcher describes the current method to diagnose food allergies. Doctors conduct an oral food challenge to determine how severe a person’s allergy is; for example, will they develop a mild rash after eating peanuts, or in extreme cases, go into anaphylactic shock? The death of a three-year-old boy in Alabama last month during an oral food challenge is a tragic reminder of the need for better diagnostic methods. While such an extreme reaction is rare—he’s the first child to die during the common allergy test—Dr. Bashar Bilgicer’s new method eliminates the danger.  

Doctors typically conduct oral food challenges after a skin prick test or blood test to determine if a person—typically a child or teenager—is allergic to a certain food and the severity of the condition. Bilgicer says the test, which can also reveal if someone has outgrown an allergy, is the best available tool to properly diagnose the extent of the condition. The patient eats small amounts of the suspected allergen, with incremental increases, while doctors observe the results—with emergency medical equipment at the ready.

“So either they do [the oral food challenge], and they have this horrible experience, or they don’t do it, because parents don’t want to put their child through it—and rightly so,” says Bilgicer, associate professor of chemical and biomolecular engineering. “Then they don’t know the extent of the child’s condition, so they just assume the worst and try to be cautious, which causes anxiety.”

Bilgicer’s method aims to deliver the same clarity as the oral food challenge, but without the danger, because the test is conducted outside of the body using only a blood sample from the patient. Bilgicer says there are 40 to 50 smaller molecular components in a peanut that can cause an allergic response. His team designed nanoparticles—dubbed “nanoallergens”—that mimic those many components.

“When you give a peanut, you’re basically giving all of those components to the patient at once, so you don’t really know which one is the culprit—the one responsible for the [allergic] response,” says Bilgicer. “With our nanoallergens, we’re dissecting these individual components [within a peanut] and presenting them one at a time [to the patient’s blood sample]—rather than giving the whole mixture—to identify, for a given patient, which one of the components is critical. That helps us achieve a much more accurate diagnosis of the extent of the condition for that patient.”

Bilgicer has developed the test with peanuts, because the allergen has been widely studied, but he says the platform could be applied to any food allergy—eliminating the fear patients experience, because they don’t know where their allergy lies on the spectrum of severity.

“The test will show that perhaps [the patient] doesn’t really have a serious condition—they’ll just get a rash—but they don’t have to worry about their life if they were exposed to a peanut. That’s a relief,” says Bilgicer. “Or, they’re potentially going to go into serious anaphylactic shock that could endanger their life, so they know they really need to be careful about avoiding the allergen.”

His strategy to pinpoint the exact component in a peanut that triggers the allergic response also reveals what would need to be inhibited, or suppressed, in each patient to treat the allergy with a drug—preventing the allergic response from occurring at all. In actuality, Bilgicer’s work to develop such a drug is what led to the idea for the allergy test, which will likely be commercialized prior to the drug.

Bilgicer’s team has tested the allergy diagnostic tool with human samples and is working to ramp up that effort, in collaboration with the Indiana University School of Medicine, to verify the clinical data and move toward submitting the method to the U.S. Food and Drug Administration (FDA). Already backed by funding from the National Institutes of Health, Bilgicer aims to raise about $500,000 more to complete early stage development.

In the next one or two years, Bilgicer envisions a business that would deliver the test in “kit” form; doctors could conduct the evaluation on-site in the clinic or send the blood sample to a centralized testing center.

“There has to be some business minds involved to decide what would be more viable as a business model, so we can provide this service to people at minimum cost and high accuracy,” says Bilgicer.

In the world of food allergies currently riddled with anxiety, Bilgicer believes his method could deliver calm and clarity to counteract the panic created by peanuts.

Bilgicer says, in extreme cases, parents and patients live their daily lives in fear of the food allergen.
Bilgicer says the idea for the diagnostic test came out of his research to develop a drug to prevent an allergic reaction.
Bilgicer says analyzing additional patient samples will prepare the tool for submission to the FDA.
  • Perspectives

    • Is Your Enterprise Ready For Digital Transformation?

      We are living in a historic era with accelerating market and technology disruptions that impact our lives and rapidly change how we do business. Cloud computing, advanced analytics, and digital technologies have the potential to transform how every company interacts with its customer. So, how do businesses keep up and (better yet) stay ahead? Enter the digital CIO. A new breed of CIO is emerging to lead companies through technology changes happening at record pace.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Big Military Diesel Engine Contract Goes to Cummins

      Columbus-based Cummins Inc. has secured a more than quarter-billion dollar U.S. Department of Defense contract. The deal involves new and remanufactured engines for the U.S. Army. The DOD says locations of where the work will be performed will be determined with each order. The contract is for procurement of new commercial, remanufactured and remanufactured conversion V903 Cummins series 600 and 675 horsepower diesel engines. Cummins bills itself as...

    • IDOE Names 'Four Star Schools'

      The Indiana Department of Education has released its list of Four Star Schools for the 2016-2017 academic year. The designation, which has been awarded for the past 30 years, aims to recognize great schools throughout the state. 

    • 'Best Places' in Indiana Reaches Record

      The Indiana Chamber of Commerce has released the 2018 list of Best Places to Work in Indiana. A record 125 companies are being honored this year and more than 50 are first-timers or returning after a year or more off the list. Employers in over two dozen communities are represented and the chamber will unveil the rankings of the Best Places honorees during a May 3 awards dinner at the Indiana Convention Center in downtown Indianapolis.

    • F&W Moving Engine Line From Mexico to Noble County

      Kendallville-based Flint & Walling Inc. is planning to on-shore some operations to Indiana. The Journal Gazette in Fort Wayne reports the manufacturer is shifting an engine production line from Mexico to Kendallville's former Superior Essex facility that it acquired a year ago. The publication says F&W is investing more than $5 million into renovations and equipment for small sump pump engines that will be used by its parent company, Louisville-based Zoeller Co.

    • Cummins to Design Combat Engines That Elude the Enemy

      The monstrous, larger-than-life military tanks of tomorrow could be powered by Hoosier ingenuity. A recent $47 million defense contract delivers marching orders for Columbus-based Cummins Inc.: develop the next-generation engine to power U.S. combat vehicles, and it must be stronger, but smaller, and elusive to enemies’ efforts to spot it.